Xbrane Biopharma AB (Xbrane) (STO:XBRANE), a commercial phase Swedish biopharmaceutical company, reported on Friday that it has been notified, via its subsidiary Primm Pharma srl, that Finchimica S.p.A, parent company of International Chemical Industry S.p.A. (ICI), has been declared bankrupt by the Court of Milan and has entered into the relevant insolvency proceeding.
ICI is Primm Pharma's contract manufacturer for its pre-clinical product candidate Spherotide.
According to the company, Primm Pharma is closely monitoring the process and will take adequate and appropriate actions to secure its interests in future production of Spherotide by ICI.
This contract manufacturing agreement for Spherotide was entered into by Primm Pharma with Finchimica as counterpart. A process for the protection of Primm Pharma's production and interests has been initiated.
Xbrane clarified that its core business, which is the development of a number of biosimilars, is not affected at all by this event.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients